Economic Atlas
Companies/Cannabis Bioscience International Holdings, Inc.
Company profile

Cannabis Bioscience International Holdings, Inc.

OTC: CBIH · Healthcare · Drug Manufacturers - Specialty & Generic
PublicHQ Houston, TX · HarrisCIK 0001411057Reports USD
#968 of 1,418 Healthcare companies by revenue68th-percentile growth
EA Score
——
Revenue TTM
$123.6k
Rev growth YoY (TTM)
-64.1%
Net income (FY)
-$548.8k
Employees
2
as of 2026-08-24
Market cap
$1.2M
as of 2026-08-24

Financials — latest annual

SEC EDGAR · USD-normalized
ConceptUSDNativeFY
Revenue$303.0k$303.0k2025
Net income-$548.8k-$548.8k2025
Operating income-$421.4k-$421.4k2025
Total assets$31.9k$31.9k2025
Liabilities$1.2M$1.2M2025
Equity-$1.2M-$1.2M2025

Revenue trend

FY2024 – FY2025 · USD
FY24
FY24
FY25

Revenue by segment

Filed disclosures · FY2024
By product
Merchandise100%
By geography

Not disclosed.

The read

What is Cannabis Bioscience International Holdings, Inc.’s revenue?

Cannabis Bioscience International Holdings, Inc. booked $303.0k in FY2025 revenue, growing 22% year over year — faster than most Healthcare companies we track, at a -181.1% net margin.

Peers · Healthcare
Medixall Group, Inc.——Atai Beckley Inc.——Kane Biotech Inc.24DNexalin Technology, Inc.34DBioAtla, Inc.15DABVC BioPharma, Inc.41D
Neighbors
Harris →
Exxon Mobil Corporation$332.2B77B+Chevron Corporation$184.4B71BConocoPhillips$51.8B76B+Quanta Services, Inc.$28.5B68BWaste Management, Inc.$25.2B82B+Phillips 66$132.4B73B
Key facts
CEODante Picazo
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersHouston, TX
ExchangeOTC: CBIH
Employees2
IPO date2023-08-08
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.